This study, published in the journal Multiple Sclerosis and Related Disorders, shows that patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue. The study, which is the first of its kind, was conducted by researchers at Mount Sinai, Celgene Cellular Therapeutics subsidiary of Celgene Corporation and collaborators at several other institutions.

READ FULL ARTICLE Curated publisher From Medical News Today